Anacor Pharmaceuticals (Anacor Pharmaceuticals) Days Sales Outstanding : 0.00 (As of Mar. 2016)

View and export this data going back to 2010. Start your Free Trial

What is Anacor Pharmaceuticals Days Sales Outstanding?

Anacor Pharmaceuticals's average Accounts Receivable for the three months ended in Mar. 2016 was $0.00 Mil. Anacor Pharmaceuticals's Revenue for the three months ended in Mar. 2016 was $17.54 Mil. Hence, Anacor Pharmaceuticals's Days Sales Outstanding for the three months ended in Mar. 2016 was 0.00.

The historical rank and industry rank for Anacor Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:

ANAC's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 71.92
* Ranked among companies with meaningful Days Sales Outstanding only.

Anacor Pharmaceuticals's Days Sales Outstanding stayed the same from Mar. 2015 (0.00) to Mar. 2016 (0.00).

Anacor Pharmaceuticals Days Sales Outstanding Historical Data

The historical data trend for Anacor Pharmaceuticals's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anacor Pharmaceuticals Days Sales Outstanding Chart

Anacor Pharmaceuticals Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Days Sales Outstanding

Get a 7-Day Free Trial

Anacor Pharmaceuticals Quarterly Data
	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16
Days Sales Outstanding	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Anacor Pharmaceuticals's Days Sales Outstanding

For the Biotechnology subindustry, Anacor Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anacor Pharmaceuticals's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anacor Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Anacor Pharmaceuticals's Days Sales Outstanding falls into.

Anacor Pharmaceuticals Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Anacor Pharmaceuticals's Days Sales Outstanding for the fiscal year that ended in Dec. 2015 is calculated as

	Days Sales Outstanding (A: Dec. 2015 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2014 )	+	Accounts Receivable (A: Dec. 2015 ))	/	count )	/	Revenue (A: Dec. 2015 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	82.355	*	365
=	0					/	82.355	*	365
=	0.00

Anacor Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2016 is calculated as:

	Days Sales Outstanding (Q: Mar. 2016 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2015 )	+	Accounts Receivable (A: Mar. 2016 ))	/	count )	/	Revenue (A: Mar. 2016 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	17.535	*	365 / 4
=	0					/	17.535	*	365 / 4
=	0.00

Anacor Pharmaceuticals (NAS:ANAC) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Anacor Pharmaceuticals Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Anacor Pharmaceuticals's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Anacor Pharmaceuticals (Anacor Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anacor Pharmaceuticals Inc (NAS:ANAC) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.anacor.com

Anacor Pharmaceuticals Inc was incorporated in Delaware in December 2000 and began business operations in March 2002. It is a biopharmaceutical company engaged in discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It has discovered, synthesized and developed eight molecules that are currently in development. The Company's main product candidates include two topically administered dermatologic compounds, tavaborole (formerly referred to as AN2690) and AN2728. Tavaborole is a topical treatment for onychomycosis, a fungal infection of the nail and nail bed. AN2728 is its main topical anti-inflammatory product candidate for the treatment of atopic dermatitis and psoriasis, chronic inflammatory skin diseases that affect millions of people. In addition, the Company has three other wholly-owned clinical product candidates; AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365 (formerly referred to as GSK2251052, or GSK '052), an antibiotic for the treatment of infections caused by Gram-negative bacteria, which previously was licensed to GlaxoSmithKline LLC (GSK). It has also discovered three other compounds that it has out-licensed for further development; one is licensed to Eli Lilly and Company (Lilly), for the treatment of an animal health indication; a second compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative (DNDi), for human African trypanosomiasis (HAT, or sleeping sickness); and a third compound is licensed to GSK for tuberculosis (TB). As of February 1, 2014, the company was the owner of record, either solely or with a collaborator, of 23 issued U.S. patents. The Company and its third-party manufacturers are subject to periodic inspections of facilities by the FDA and other authorities, including procedures and operations used in the testing and manufacture of its products to assess its compliance with applicable regulations.

Executives

Keith R Leonard	director	ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
William Jl Rieflin	director	NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Anders D Hove	director	30 ROCKEFELLER PLAZA, SUITE 5508, NEW YORK NY 10112
Lucy Shapiro	director	10210 GENETIC CENTER COURT, SAN DIEGO CA 92121
Graeme Bell	officer: Executive VP and CFO	1324 WAVERLY ROAD, GLADWYNE PA 19035
Ryan T Sullivan	officer: EVP and General Counsel	C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07855
Wendall Wierenga	director	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Paul L Berns	director, officer: President and CEO	11080 CIRCLEPOINT RD., STE, 200, WESTMINSTER CO 80020
Mark Leschly	director	RHO CAPITAL PARTNERS, INC., 152 W 57TH ST 23RD FL, NEW YORK NY 10019
Geoffrey M. Parker	officer: Executive Vice President & CFO	15 RIORDAN PLACE, MENLO PARK CA 94025
Paul H Klingenstein	director	428 UNIVERSITY AVE, C/O ACCEL PARTNERS, PALO ALTO CA 94301
David P Perry	director, officer: President and CEO	1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303
Rho Management Ventures Iv Llc	10 percent owner	124 DUNE RD, QUOGUE NY 11959
Rho Ventures Iv Qp Lp	10 percent owner	124 DUNE RD, QUOGUE NY 11959
Rho Ventures Iv Lp	10 percent owner	124 DUNE ROAD, QUOGUE NY 11959

Anacor Pharmaceuticals (Anacor Pharmaceuticals) Headlines

From GuruFocus

Arctos NorthStar Acquisition Corp. Announces Redemption of Class A Ordinary Shares

By Business Wire Business Wire • 02-10-2023

Stemming from SEC Guidance Concerning Balance Sheet Treatment of Warrants, Arctos NorthStar Acquisition Corp. Announces Receipt of NYSE Continued Listing Standard Notice

By Business Wire Business Wire • 06-02-2021